Related Experiment Videos
[Progress of EBNA1/oriP-based plasmid applied in gene therapy]
1Institute of Viral Disease Control and Prevention, China CDC, Beijing 100052, China.
Sheng Wu Gong Cheng Xue Bao = Chinese Journal of Biotechnology
|August 20, 2005
Summary
EBV plasmid vectors using EBNA1/oriP elements significantly improve gene delivery and expression for various diseases. These enhanced nonviral gene therapy systems show promise in treating cancer, congenital, and inflammatory conditions.
Area of Science:
- Molecular Biology
- Gene Therapy
- Biotechnology
Background:
- Nonviral gene delivery systems often suffer from low efficiency and poor gene expression.
- The EBNA1/oriP system maintains plasmids as episomes, aiding nuclear transport and gene expression.
Purpose of the Study:
- To review preclinical gene therapy studies utilizing EBV plasmid vectors.
- To highlight the advantages of EBNA1/oriP based plasmids in enhancing gene delivery and expression for various diseases.
Main Methods:
- Review of preclinical studies involving EBV plasmid vectors (EBNA1/oriP based).
- Application in gene therapy for malignancies, congenital diseases, and inflammatory conditions.
Main Results:
- EBNA1/oriP plasmids enhanced transfection rates, gene expression magnitude, and longevity.
- Demonstrated efficacy in cancer therapy (e.g., HCC with HSV1-TK), congenital diseases (ADA gene), and inflammatory diseases (sTNFR-IgG Fc).
- Achieved significantly higher gene expression levels and therapeutic effects compared to conventional plasmids.
Conclusions:
- EBNA1/oriP based plasmids offer significant advantages for gene therapy in cancer, congenital, and inflammatory diseases.
- The EBNA1/oriP element holds potential for engineering human artificial chromosomes for controllable gene therapy.